Urolithin A for Joints: What to Know

Joints depend on a surprisingly delicate tissue, and that tissue depends on healthy cellular energy. The research linking urolithin A to joints is real, but it is early and mostly preclinical. Here is an honest look at what has actually been shown.

What cartilage is, and why it is vulnerable

A joint is where two bones meet, and the surfaces that glide against each other are covered in cartilage, a smooth, cushioning tissue that absorbs load and reduces friction. Cartilage is maintained by a single type of cell called the chondrocyte. Chondrocytes are unusual: cartilage has no blood supply of its own, so these cells operate in a low-oxygen, nutrient-limited environment and are responsible for both building and maintaining the surrounding matrix. When chondrocytes struggle, the cartilage they maintain can gradually lose quality.

This is condition-adjacent territory, so let us be clear at the outset. Nothing here is about treating arthritis, osteoarthritis, or any joint disease. This page covers the everyday cell biology of joint tissue and the emerging structure and function research around urolithin A. Persistent joint pain, stiffness, or swelling is something to bring to your doctor, not something to self-manage with a supplement.

The mitochondrial connection in joint tissue

Mitochondria are the structures inside cells that turn nutrients and oxygen into usable energy, and they also help cells manage stress. In chondrocytes, mitochondrial function matters a great deal. Research into joint tissue has increasingly pointed to mitochondrial dysfunction in chondrocytes as one feature associated with cartilage stress, with tired or damaged mitochondria contributing to oxidative stress inside the cell. When the cell cannot clear those worn mitochondria efficiently, the resulting stress is thought to make it harder for chondrocytes to maintain healthy cartilage.

The cellular process for clearing damaged mitochondria is called mitophagy, a form of quality control in which cells tag and recycle worn-out mitochondria so fresher ones can take over. Our explainer on what mitophagy is covers this in plain language. Mitophagy tends to become less efficient with age, which is part of why mitochondrial health has become a theme across aging research, including in tissues like cartilage.

What is urolithin A

Urolithin A is a gut postbiotic. Plants do not make it directly. Your gut microbiome converts ellagitannins, compounds found in pomegranates, walnuts and certain berries, into urolithin A, and not everyone's microbiome does this well. That variability is a major reason a standardized supplement has become a research subject rather than relying on diet alone. For a fuller primer, see the urolithin A guide and our overview of foods high in urolithin A. The scientific interest in urolithin A rests on one observed action: it supports mitophagy, the recycling of worn mitochondria.

The evidence, organized by strength

For joints specifically, it is essential to be honest about the tiers of evidence, because the joint research is at an earlier stage than the muscle research.

The joint-specific research is preclinical

The study most often cited for joints is D'Amico et al. 2022 in Aging Cell (PubMed 35778837). This is important to label clearly: it was conducted in osteoarthritis models, meaning animal and cell systems, not in human patients. In those models, urolithin A was associated with support for joint and cartilage mitochondrial health, consistent with its mitophagy mechanism. It is a genuinely interesting result and a reasonable scientific rationale, but it is preclinical. It does not demonstrate that urolithin A relieves joint symptoms, protects cartilage, or does anything for arthritis in people. Early and preclinical research is exploring these possibilities; it has not proven them.

The foundational preclinical mechanism

The mechanism itself traces back to Ryu et al. 2016 in Nature Medicine, also preclinical, in worms and rodents. That work showed urolithin A induced mitophagy and improved muscle function in animals, and extended lifespan in C. elegans. It is the origin of the mitophagy story and it is compelling as a mechanism, but it is animal and cell research. Read together with the joint models, these studies build a coherent laboratory rationale for why cartilage-maintaining cells might benefit from better mitochondrial quality control, without yet proving a human joint outcome.

What has actually been proven in humans, and where

To keep the picture honest, the human trials on urolithin A have centered on muscle, not joints. Andreux et al. 2019 in Nature Metabolism established safety and a mitochondrial gene-expression signature at doses up to 1,000 mg per day. Liu and D'Amico et al. 2022 in JAMA Network Open (5:e2144279) reported improved muscle endurance in older adults over about four months. Singh et al. 2022 in Cell Reports Medicine (PubMed 35584623) reported gains in muscle strength and exercise performance in middle-aged adults at 500 and 1,000 mg. These are summarized in our clinical studies overview and our page on urolithin A for muscle. They are strong human evidence for muscle-related outcomes, and they matter to joint-minded readers mainly because supporting the muscles around a joint is part of overall joint support, but they are not joint studies.

Honest limitations

A 2024 systematic review in Ageing Research Reviews on targeting aging with urolithin A in humans concluded that the human evidence is still emerging, with short trials and modest sample sizes, and the joint-specific human data are essentially not there yet. So the honest summary for joints is this: a plausible mechanism, encouraging preclinical results, and no human joint trials to point to. Urolithin A is not a treatment for arthritis or any joint condition, and it is not a replacement for physical therapy, medication, or medical care. If you have joint pain, stiffness, swelling, or a diagnosed joint condition, please see your doctor.

Practical guidance

If you are considering urolithin A as part of a routine that supports mitochondrial health, the clinically studied range is 500 to 1,000 mg per day, taken consistently, with benefits in human muscle trials appearing over weeks to months; see how long urolithin A takes to work. For joints specifically, the evidence-based fundamentals still do the heavy lifting: maintaining a healthy weight to reduce joint load, staying active with movement your joints tolerate, building the muscle that supports your joints, and following any plan your doctor or physical therapist gives you. If you want to compare products and quality standards, our roundup of the best urolithin A gummies explains what to look for, including third-party testing and transparent dosing.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This guide is educational and is not a substitute for advice from a qualified healthcare provider.